IPP Bureau
Sun Pharma gets exclusive patent licence for Vortioxetine
By IPP Bureau - March 30, 2022
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
Sara Gutierrez joins SHL as the Chief Science Officer
By IPP Bureau - March 30, 2022
The science leader comes with a rich experience in the employment testing industry
GenScript wins Best CDMO award for the third time
By IPP Bureau - March 30, 2022
The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".
USFDA approves CartiHeal's implant for the treatment of cartilage and osteochondral defects
By IPP Bureau - March 30, 2022
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint
NAMSA to acquire European-based Medanex clinic
By IPP Bureau - March 30, 2022
World-leading companies, as well as small innovative research groups, regularly partner with Medanex for their outstanding cardiovascular services and timely, efficacious study outcomes.
X-Chem’s Noor Shaker awarded for achievements in AI for drug discovery
By IPP Bureau - March 30, 2022
Shaker is one of six receiving an individual award, which recognizes people, organizations and products bringing AI to life and applying it to solve real problems
ASC Therapeutics gets green light to advance gene therapy for Hemophilia A
By IPP Bureau - March 30, 2022
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
TDB approves funding for MIM in MedTech
By IPP Bureau - March 30, 2022
Technology Development Board supports commercialisation of Metal Injection Molding of implants
Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes
By IPP Bureau - March 29, 2022
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
Dupixent is a star in Sanofi’s immunology strategy
By IPP Bureau - March 29, 2022
Dupixent peak sales ambition raised to more than €13 billion
Dysval gets regulatory approval in Japan
By IPP Bureau - March 29, 2022
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
USFDA clears IND application for an intranasal RSV vaccine
By IPP Bureau - March 29, 2022
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Carestream Health India showcases two new products at IRIA
By IPP Bureau - March 29, 2022
As a partner with IRIA, the company had a significant booth presence on-ground during the conference.
Lawrence Berkeley lab offers trial kit for CRAGE Genome Engineering Tool
By IPP Bureau - March 29, 2022
Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
Alembic Pharma acquires 100% stake in Aleor Dermaceuticals
By IPP Bureau - March 29, 2022
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
